1. IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis
- Author
-
Jason S. Carroll, Stacey E. P. Joosten, Rasmus Siersbæk, Andrew R. Green, Wilbert Zwart, Danya Cheeseman, Igor Chernukhin, Emad A. Rakha, Rebecca Broome, Evangelia K. Papachristou, Sankari Nagarajan, Soleilmane Omarjee, Ruben Alvarez-Fernandez, Valentina Scabia, Julia P. G. Jones, Clive D'Santos, Kamal Kishore, Simon J Johnston, Sanjeev Kumar, Silvia Glont, Cathrin Brisken, Alasdair Russell, Sarah J. Aitken, Chemical Biology, Kumar, Sanjeev [0000-0001-6017-1117], Aitken, Sarah [0000-0002-1897-4140], Kishore, Kamal [0000-0002-4650-8745], Carroll, Jason [0000-0003-3643-0080], and Apollo - University of Cambridge Repository
- Subjects
0301 basic medicine ,pioneer factor ,Cancer Research ,Estrogen receptor ,Kaplan-Meier Estimate ,Mice, SCID ,SDG 3 – Goede gezondheid en welzijn ,Metastasis ,STAT3 ,mouse intraductal xenograft model ,0302 clinical medicine ,Breast cancer ,Mice, Inbred NOD ,Neoplasm Metastasis ,skin and connective tissue diseases ,Fulvestrant ,Cancer ,Mice, Knockout ,3. Good health ,Gene Expression Regulation, Neoplastic ,Enhancer Elements, Genetic ,Oncology ,030220 oncology & carcinogenesis ,MCF-7 Cells ,Female ,Signal transduction ,medicine.drug ,Signal Transduction ,estrogen receptor ,STAT3 Transcription Factor ,Antineoplastic Agents, Hormonal ,Breast Neoplasms ,Biology ,03 medical and health sciences ,breast cancer ,SDG 3 - Good Health and Well-being ,medicine ,Animals ,Humans ,metastasis ,Interleukin-6 ,Gene Expression Profiling ,Estrogen Receptor alpha ,medicine.disease ,Xenograft Model Antitumor Assays ,IL6 ,030104 developmental biology ,Cancer research ,enhancers ,FOXA1 ,Estrogen receptor alpha - Abstract
The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a key oncogenic pathway, which has been thought to be functionally connected to estrogen receptor α (ER) in breast cancer. We demonstrate that IL6/STAT3 signaling drives metastasis in ER+ breast cancer independent of ER. STAT3 hijacks a subset of ER enhancers to drive a distinct transcriptional program. Although these enhancers are shared by both STAT3 and ER, IL6/STAT3 activity is refractory to standard ER-targeted therapies. Instead, inhibition of STAT3 activity using the JAK inhibitor ruxolitinib decreases breast cancer invasion in vivo. Therefore, IL6/STAT3 and ER oncogenic pathways are functionally decoupled, highlighting the potential of IL6/STAT3-targeted therapies in ER+ breast cancer.
- Published
- 2020